Universal reference book for medicines
Name of the drug: REXOD (REXOD)

Active substance: nonappropriate

Type: Antioxidant drug

Producer: GosNII OCHB (Russia)
Composition, form of production and packaging
Lyophilizate for the preparation of a solution for
intravenous administration of 1 vial.

superoxide dismutase 1.6 million units

bottles (5) - cardboard pallets (1) - cardboard packs.

ampoules (5) - cardboard pallets (1) - cardboard packs.

Lyophilizate for the preparation of a solution for intravenous administration of 1 vial.

superoxide dismutase 3.2 million units

bottles (5) - cardboard pallets (1) - cardboard packs.

ampoules (5) - cardboard pallets (1) - cardboard packs.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Superoxide dismutase is an endogenous acceptor of free oxygen radicals, the excessive accumulation of which in the cell plays an important role in the development of oxygen-dependent pathological processes (hypoxia, inflammation, intoxication).
Superoxide dismutase removes superoxide radicals and prevents the formation of other radicals more dangerous to the body: hydroxyl radical and singlet oxygen. Besides, superoxide dismutase prevents the accumulation of neutrophils in the inflammatory focus, which secrete significant amounts of lysosomal enzymes that destroy nearby tissues.
Rexod normalizes the oxidative processes taking place with the participation of free radicals of oxygen and prevents the oxidative modification of proteins, as well as the destruction of biomembranes associated with the activation of lipid peroxidation.

PHARMACOKINETICS

With iv injection of the drug Rexod, the dynamics of its concentration in the blood corresponds to a 2-chamber model.
T 1/2 of the preparation is on the order of 30 В± 4 min. The ratio of the stationary and initial V d is of the order of 2, i.e. the preparation is well distributed into tissues. Evidence of the accumulation of Rexod in the body and the possibility of its cumulation studies have not been revealed.
INDICATIONS

- comprehensive prevention of intraoperative complications in endoprosthetics of large joints, using bone cement.

DOSING MODE

In / in, drip, during surgery, before using bone cement.
9.6 million units pre-dissolved in 100 ml of saline for 10-15 minutes.
The ready-made solution should be used immediately after preparation, not mixed with other medicinal products.

The use of Rexod is not a contraindication to the use of other drugs.

SIDE EFFECT

Allergic reactions are possible.
For other preparations of superoxide dismutase, cases of development of anaphylactic reactions (including shock) have been described.
CONTRAINDICATIONS

- age up to 18 years;

- Pregnancy;

- lactation period;

- Hypersensitivity to the drug.

PREGNANCY AND LACTATION

Contraindicated in pregnancy and lactation.

APPLICATION FOR CHILDREN

Contraindicated in patients under the age of 18 years.

OVERDOSE

The drug is not toxic.
Cases of overdose are unknown.
DRUG INTERACTION

Clinically significant interactions of the drug are not described.
In endoprosthetics of large joints, the therapeutic efficacy of the drug is indicated by the combined administration of Rexod with preparations of sodium fumarate.
TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

Store at temperatures between 4 В° and 10 В° C.
Keep out of the reach of children. Shelf life - 2 years. Do not use after the expiration date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!